|
|
|
|
|
|
by mejiaoneto
2074 days ago
|
|
|
Yes. Any solid tumor that is accesible for an injection and we have reason to suspect it would be sensitive to doxorubicin, would fit the criteria of this phase 1 study.
For more info on the clinical trial please visit:
https://clinicaltrials.gov/ct2/show/NCT04106492 |
|
|